Parkinson's Disease and Biomarkers

View overview page
4:28
Update on biomarkers in isolated RBD and future directions
Mitchell Miglis • 3 Mar 2022
3:42
Questioning the Braak hypothesis in Parkinson’s disease
Alberto Espay • 9 Sep 2021
2:49
Is clearing α-synuclein enough to treat Parkinson’s disease?
Alberto Espay • 9 Sep 2021
2:13
Research focuses in atypical parkinsonism
Irene Litvan • 22 Sep 2021
1:51
The future of imaging in Parkinson’s disease
Sofia Reimão • 20 Sep 2021
2:20
Predicting progression of iRBD to neurodegenerative disease
Claudio Bassetti • 23 Sep 2021
6:48
Future avenues of precision medicine in Parkinson’s: predicting impulse control disorders
Alice Chen-Plotkin • 20 Sep 2021
6:58
Cerebral dopamine neurotrophic factor: first-in-human trial in moderately advanced PD
Henri Huttunen • 20 Sep 2021
1:29
How should Parkinson’s disease subpopulations be defined?
Chin-Hsien Lin • 9 Sep 2021
3:49
A standardized multimodal MRI protocol for Parkinsonism
Sofia Reimão • 20 Sep 2021
1:57
Diagnostic potential of multimodal MRI in Parkinson’s disease
Sofia Reimão • 20 Sep 2021
1:40
What’s needed to improve Parkinson’s disease subgrouping?
Oscar Gershanik • 16 Sep 2021
4:32
Diagnosing parkinsonism with atypical features: a classification system
Oscar Gershanik • 16 Sep 2021
2:02
The current use of biomarkers in Parkinson’s disease
Brit Mollenhauer • 4 Sep 2020
1:25
Challenges hampering clinical utility of fluid biomarkers in Parkinson’s disease
Brit Mollenhauer • 4 Sep 2020
4:27
The MIND Initiative: molecular characterization in Parkinson’s disease
Alice Chen-Plotkin • 20 Sep 2021
The content of VJNeurology is intended for healthcare professionals